Geritrex Acquires PurinePharma
November 9, 2015
Geritrex, a BelHealth Investment Partners portfolio company, has acquired the business and assets of PurinePharma, a private-label manufacturer and distributor of OTC liquid nasal, allergy, and cough & cold products based in Massena, New York. The add-on expands Geritrex's manufacturing capabilities into liquid dosage forms, provides access to the retail private-label channel and export markets, and adds a CGMP-approved manufacturing facility in upstate New York.
- Buyers
- Geritrex, BelHealth Investment Partners
- Targets
- PurinePharma
- Platforms
- Geritrex
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Pfizer's Hospital Business Acquires Arixa Pharmaceuticals
October 22, 2020
Pharmaceuticals
Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.
-
AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction
December 31, 2022
Healthcare Services
AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.
-
Idera Pharmaceuticals Acquires Aceragen
September 28, 2022
Biotechnology
Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.
-
APNAR Pharma Acquires Aurex Laboratories
February 3, 2022
Pharmaceuticals
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
-
Actylis Acquires Pharm-Rx
October 7, 2024
Pharmaceuticals
Actylis has acquired Pharm-Rx, a Saddle Brook, New Jersey-based supplier of specialty ingredients for the vitamin, mineral and supplement (VMS), OTC and pharmaceutical markets. The deal expands Actylis' nutrition and OTC capabilities and supplier partnerships; Pharm-Rx will continue to operate under its brand and Mark Bostel will become President, Global Nutrition and OTC for Actylis. Financial terms were not disclosed.
-
Norwell Consumer Healthcare Acquires Boyd Pharmaceuticals' Canadian OTC Brands
July 5, 2023
Pharmaceuticals
Norwell Consumer Healthcare Inc. has entered a definitive agreement to acquire a portfolio of assets from Boyd Pharmaceuticals, including the Colace, Colace Glycerin, Dequadin, Allenburys and Gelusil brands in Canada. The asset purchase strengthens Norwell's gastroenterology and cough & cold portfolio and supports accelerated growth of its consumer OTC business.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.